Della Torre S, de Nucci G, Lombardi PM, Grandi S, Manes G, Bollina R. Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report. World J Clin Oncol 2021; 12(6): 500-506 [PMID: 34189072 DOI: 10.5306/wjco.v12.i6.500]
Corresponding Author of This Article
Silvia Della Torre, MD, Doctor, Oncology Unit, ASST Rhodense, Corso Europa 2, Rho 20017, Italy. sdellatorre@asst-rhodense.it
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: Della Torre S is the guarantor of the article; Lombardi PM contributed to data analysis and interpretation; de Nucci G drafted and revised the article, and issued final approval of the article; Grandi S provided critical revision of the article, and issued final approval of the article; Manes G provided critical revision of the article for important intellectual content, and issued final approval of the article; Bollina R contributed to the drafting of the article, data analysis and interpretation, and final approval of the article; all authors approved the final version of the article, including the authorship list.
Informed consent statement: The patient provided consent to the writing and publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Silvia Della Torre, MD, Doctor, Oncology Unit, ASST Rhodense, Corso Europa 2, Rho 20017, Italy. sdellatorre@asst-rhodense.it
Received: October 23, 2020 Peer-review started: October 23, 2020 First decision: December 4, 2020 Revised: December 24, 2020 Accepted: March 3, 2021 Article in press: March 3, 2021 Published online: June 24, 2021
Core Tip
Core Tip: Neuroendocrine gastrointestinal tumors are rare with different clinical behaviors. Prognostic factors are tumor differentiation, Ki-67 index and the presence of distant metastases. Most of these tumors are well differentiated neuroendocrine tumors with a good prognosis and a 5-year overall survival of 60%-90%. Surgery is the gold standard treatment in local and metastatic disease, while radiotherapy is ineffective. Poorly differentiated neuroendocrine carcinomas represent only 5%-10% of digestive neuroendocrine gastrointestinal tumors. Here we describe the rare case of a patient diagnosed with poorly differentiated rectal metastatic neuroendocrine carcinoma treated with a different treatment approach and with complete remission after 5 years.
